For what concerns the tumor type, patients with PD-L1 positive tumor significantly achieved more responses than PD-L1 negative, with an absolute difference of 22.8% for melanoma (95% CI 12.5–30.3) and 8.7% for NSCLC (95% CI 1.1–15.5) as shown in Fig 4. The gene discussed is CD274; the disease is non-small cell lung carcinoma.